Management of Diabetes in Kidney Transplant Recipients

Initial Therapy

• For kidney transplant recipients with diabetes and eGFR ≥30 ml/min/1.73 m², metformin should be used as first-line therapy, followed by SGLT2 inhibitors when appropriate, with GLP-1 receptor agonists as preferred add-on therapy when needed for glycemic control, as recommended by the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines 1, 2

Medication Eligibility and Monitoring

• Assess kidney function (eGFR) to determine medication eligibility, and start with metformin if eGFR ≥30 ml/min/1.73 m², with monitoring of kidney function at least every 3-6 months if eGFR <60 ml/min/1.73 m², and monitoring of vitamin B12 levels after 4 years of therapy, as recommended by the Endocrine Society and Kidney International guidelines 1, 3, 4, 1
• The recommended metformin dosing based on eGFR is as follows:

Add-on Therapy

• Add SGLT2 inhibitor if eGFR permits (≥30 ml/min/1.73 m²), which can reduce the relative risk of primary renal outcomes by 30% and provide benefits independent of glycemic effects, with a low risk of hypoglycemia when used with metformin, as recommended by the European Heart Journal and American Geriatrics Society 5, 2, 1
• Add GLP-1 receptor agonists as preferred add-on therapy when needed for glycemic control, choosing agents with documented cardiovascular benefits, especially for patients with eGFR <30 mL/min/1.73m², as recommended by the Endocrine Society and Kidney International guidelines 5, 2, 1, 6

Discontinuation and Alternative Therapy

• Discontinue SGLT2 inhibitors when eGFR falls below 30 ml/min/1.73 m², and consider alternative first-line options, including GLP-1 receptor agonists, DPP-4 inhibitors, and insulin therapy, as recommended by the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines and the American Geriatrics Society 1, 2, 7
• For patients with type 2 diabetes and CKD, GLP-1 receptor agonists with proven cardiovascular benefit and DPP-4 inhibitors (with appropriate dose adjustments) are recommended as preferred options, especially for patients with eGFR <30 mL/min/1.73m², as recommended by the Endocrine Society and Kidney International guidelines 5, 2, 1, 6

Special Considerations

• Less stringent glycemic targets (A1c 7-8%) are appropriate for elderly patients with severe CKD, given their age and comorbidities, with patient education on hypoglycemia symptoms and management, as recommended by the American Geriatrics Society and Endocrine Society 1, 8, 9
• Long-term metformin use may cause vitamin B12 deficiency, and periodic monitoring is recommended, especially in patients with anemia or peripheral neuropathy, as recommended by the Kidney International guidelines and the Endocrine Society 10, 11, 12
• The American Geriatrics Society recommends dose reduction or interval extension for certain medications (e.g., acyclovir, amantadine, ciprofloxacin, and gabapentin) when creatinine clearance (CrCl) is reduced, and glyburide and spironolactone should not be used with significant renal impairment due to increased hypoglycemia and hyperkalemia risk, as recommended by the American Geriatrics Society and Endocrine Society 7, 6